Please classify this clinical trial as a success (1), failure (0), or indeterminate (-1) based on the following classification system:


Classification System:
Success (1):
- Completed, Early positive outcome
- Completed, Positive outcome/primary endpoint(s) met

Failure (0):
- Terminated, Lack of efficacy
- Completed, Negative outcome/primary endpoint(s) not met
- Terminated, Safety/adverse effects
- Terminated, Poor enrollment

Indeterminate (-1):
- Completed, Outcome indeterminate
- Completed, Outcome unknown
- Terminated, Business decision - Drug strategy shift
- Terminated, Business decision - Other
- Terminated, Business decision - Pipeline reprioritization
- Terminated, Lack of funding
- Terminated, Other
- Terminated, Planned but never initiated
- Terminated, Unknown


Here is the trial information:

NCT ID: NCT00000134
Title: Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
Overall Status: COMPLETED
Phases: PHASE3
Enrollment: 279 (ACTUAL)

=== DETAILED OUTCOME MEASURES ===

1. PRIMARY OUTCOME: Morbidity
   Description: To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis.
   Time Frame: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
   Unit of Measure: participants
   Results:
      Results:
        Intravenous Foscarnet: 88
        Intravenous Ganciclovir: 93
        Combination Therapy: 93

=== ADVERSE EVENTS SUMMARY ===
Time Frame: 1 year, 4 months

Group: Intravenous Foscarnet
  Serious Adverse Events: 32/88 participants (36.4%)
  Other Adverse Events: 7/88 participants (8.0%)

Group: Intravenous Ganciclovir
  Serious Adverse Events: 41/93 participants (44.1%)
  Other Adverse Events: 7/93 participants (7.5%)

Group: Combination Therapy
  Serious Adverse Events: 51/93 participants (54.8%)
  Other Adverse Events: 10/93 participants (10.8%)

Top Serious Adverse Events:
  Neutropenia (Blood and lymphatic system disorders):
    Intravenous Foscarnet: 32/88 (36.4%)
    Intravenous Ganciclovir: 41/93 (44.1%)
    Combination Therapy: 51/93 (54.8%)
  Thrombocytopenia (Blood and lymphatic system disorders):
    Intravenous Foscarnet: 14/88 (15.9%)
    Intravenous Ganciclovir: 8/93 (8.6%)
    Combination Therapy: 15/93 (16.1%)

Based on the above detailed information, especially focusing on the statistical significance of outcomes, p-values, confidence intervals, and any adverse events, classify this trial as 1 (success), 0 (failure), or -1 (indeterminate). Return ONLY the classification number.